Wall Street analysts forecast that Blueprint Medicines (BPMC) will report quarterly loss of $2.04 per share in its upcoming release, pointing to a year-over-year increase of 23$67.28 million, exhibiting an increase of 73.5% compared to the year-ago quarter. Over the last 30 days, there has been an upward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsiderati ...